• To protect public health by mobilising the best scientific resources existing within the European Union (see Articles 49 and 51(a)) • To promote health care through the effective regulation of new pharmaceuticals and better information for users and health professionals (see Article 51(i)) • To facilitate the free circulation of pharmaceuticals within the European single market (see Article 51, first paragraph) • To support the European pharmaceutical research and development industry by developing efficient, effective and responsive operating procedures (see Article 51, first paragraph) • To support efforts in international co-operation (see Article 51(f)) 13